Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Turns Again To Daewoong For Co-promotion In South Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Merck & Co. Inc. signed a co-promotion deal with Korea's Daewoong Pharmaceutical Co. Ltd. to sell Merck's Vytorin (ezetimibe/simvastatin) in Korea, adding to the companies' similar agreements for Fosamax (alendronate) and Januvia (sitagliptin), which have been sold in Korea since 2008

You may also be interested in...



Daewoong Inks Autotelic Deal To Help International Expansion

After a fairly smooth launch for its combination drug Olostar in South Korea last year, Daewoong is now taking the product into global markets as part of its international expansion strategy.

Korea’s Daewoong Pharmaceutical Joins With Turkey’s Abdi Ibrahim On Renal, Foot Ulcer Treatments

South Korean drug companies are looking to make inroads into emerging markets through a combination of distribution deals, and Daewoong Pharmaceutical has made its move through a deal with Turkey’s leading drug company.

Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex

SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex

Related Content

UsernamePublicRestriction

Register

SC078665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel